US Patent

US7968543 — Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Method of Use · Assigned to Ambit Bioscience Corp · Expires 2029-08-15 · 3y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of administering the drug quizartinib dihydrochloride to treat proliferative diseases in humans.

USPTO Abstract

Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Further, pharmaceutical formulations are provided. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3661 — quizartinib-dihydrochloride
U-3661 — quizartinib-dihydrochloride

Patent Metadata

Patent number
US7968543
Jurisdiction
US
Classification
Method of Use
Expires
2029-08-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.